Donnelly P K, Lennard T W, Proud G, Taylor R M, Henderson R, Fletcher K, Elliott W, Ward M K, Wilkinson R
Br Med J (Clin Res Ed). 1985 Oct 12;291(6501):1001-4. doi: 10.1136/bmj.291.6501.1001.
Continuous ambulatory peritoneal dialysis is a new and increasingly popular method of routine dialysis, but its effect on renal transplantation is uncertain. A non-randomised comparison was made of the outcome of grafting in patients who had been treated before transplantation with continuous ambulatory peritoneal dialysis with that in patients treated with haemodialysis. During the five years, 1979-84, after continuous ambulatory peritoneal dialysis was introduced to Newcastle upon Tyne 220 patients have received transplants after either continuous ambulatory peritoneal dialysis (61 patients) or haemodialysis (159 patients). During follow up no significant differences occurred in survival of patients or grafts between the two treatment groups. One year after transplantation the percentages of survivors who had received continuous ambulatory peritoneal dialysis and haemodialysis were 88% and 91% respectively, and overall graft survival was 66% and 72%, respectively. A multiple regression model was used to allow for differences among patients--for example, duration of dialysis and number of preoperative transfusions--on the survival of grafts. When only first cadaver grafts were considered (in 152 patients) graft survival (non-immunological failures excluded) was not significantly different between the patients treated with continuous ambulatory peritoneal dialysis and haemodialysis. Continuous ambulatory peritoneal dialysis is not a risk factor in renal transplantation, and its continued use in treatment of potential renal graft recipients is recommended.
持续性非卧床腹膜透析是一种新型且日益普及的常规透析方法，但其对肾移植的影响尚不确定。对移植前接受持续性非卧床腹膜透析治疗的患者与接受血液透析治疗的患者的移植结局进行了非随机比较。在1979年至1984年的五年间，持续性非卧床腹膜透析引入泰恩河畔纽卡斯尔后，220例患者在接受持续性非卧床腹膜透析（61例患者）或血液透析（159例患者）后接受了移植。在随访期间，两个治疗组患者或移植物的存活率没有显著差异。移植后一年，接受持续性非卧床腹膜透析和血液透析的存活者百分比分别为88%和91%，总体移植物存活率分别为66%和72%。使用多元回归模型来考虑患者之间的差异，例如透析时间和术前输血次数，对移植物存活的影响。当仅考虑首次尸体供肾移植（152例患者）时，接受持续性非卧床腹膜透析和血液透析治疗的患者之间的移植物存活（排除非免疫性失败）没有显著差异。持续性非卧床腹膜透析不是肾移植的危险因素，建议继续用于潜在肾移植受者的治疗。
